Perioperative biomarker monitoring to spot complications after colorectal and gastric cancer surgery
Official title: Temporal Profiles of Inflammatory Markers in General Oncologic Surgery
Run by Bucharest Emergency Hospital · NCT07881133 · Data updated 2026-11-12
This randomized trial tests whether checking inflammatory and metabolic biomarkers during the perioperative period helps detect postoperative problems early in adults having colorectal or gastric cancer surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 320 (estimated) |
| Sponsor | Bucharest Emergency Hospital Academic / other |
| Locations | 1 site (Bucharest, Bucharest) |
| Status | Recruiting |
| Started | February 25, 2026 |
| Main results expected | January 2029 |
| Study ends | January 2029 |
| Registry record updated | October 19, 2026 |
| Trial ID | NCT07881133 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older with colorectal or gastric cancer scheduled for elective abdominal oncologic surgery, ASA II-IV, able to consent.
✕Probably not a fit
Patients who do not experience postoperative complications or whose biomarker levels do not correlate with such events may not experience a clear benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-center randomized controlled trial at Bucharest Emergency Clinical Hospital. Adults undergoing elective colorectal or gastric cancer surgery are assigned to either enhanced recovery after surgery (ERAS) with structured biomarker monitoring or standard postoperative care. The study measures biomarkers such as procalcitonin, lactate, and glucose after surgery to see if their levels relate to complications like infections or anastomotic leakage within 30 days, along with length of stay, readmissions, and mortality. Randomization uses stratified block methods, and biomarker data are collected at predefined postoperative time points. The goal is to determine if biomarker-guided care can improve early complication detection and postoperative outcomes.
Why it matters
Potential benefit: If successful, this approach could enable earlier detection of complications and potentially shorten hospital stays and improve recovery.
How similar studies have gone: Previous research suggests biomarkers can reflect postoperative risk, but the specific perioperative monitoring with ERAS integration is a developing area with limited definitive evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients aged 18 years or older. * Patients diagnosed with colorectal or gastric cancer. * Patients scheduled for elective abdominal oncologic surgery. * Patients classified as ASA physical status II-IV. * Patients who provide written informed consent to participate in the study. Exclusion Criteria: * Patients with known autoimmune or immunological diseases that may significantly influence inflammatory biomarker levels. * Patients diagnosed with inflammatory bowel disease (IBD). * Patients who refuse to participate or do not provide written informed consent.
Where it's running
-
Emergency Clinical Hospital Bucharest
Bucharest, Bucharest, Romania Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers
This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.
-
BHB810 in advanced gastric and GEJ cancer (early-phase)
This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.
-
Biopsy and Resection Growth Patterns in Colorectal Peritoneal Cancer
This study tests whether peritoneal growth patterns seen on small biopsies during staging laparoscopy match the patterns found in later surgical specimens for adults with colorectal peritoneal metastases.
-
RC148 plus chemotherapy as first-line treatment for unresectable or metastatic colorectal cancer
This study tests RC148 with standard chemotherapy as the first treatment for people with unresectable or metastatic colorectal cancer to see if it helps more than current therapy.
-
Moving the uterus, ovaries, and fallopian tubes out of the pelvis before whole pelvic radiation to preserve fertility.
This trial tries moving the uterus, ovaries, and fallopian tubes out of the pelvis before whole pelvic radiation in women aged 18–40 who want to preserve their ability to have children.
-
Immune response to histotripsy in colorectal cancer liver metastases
This pilot will test whether histotripsy, a noninvasive liver tumor treatment, changes blood T‑cell responses in people with colorectal cancer that has spread to the liver.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.